Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GemOx with or without rituximab as first-line treatment for elderly aggressive B-cell lymphoma
ChiCTR-TRC-12002256Phase 3Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, oxaliplatin and rituximab in aggressive B-cell lymphoma (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: overall response rate and safety and toxicity. Started Jan 2012; status: completed.
02
Drugs
gemcitabineoxaliplatinrituximab
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on ChiCTR-TRC-12002256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002256.